Candriam S.C.A. Has $8.15 Million Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC

Candriam S.C.A. lessened its holdings in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) by 2.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,172,387 shares of the company’s stock after selling 32,820 shares during the quarter. Candriam S.C.A. owned 1.69% of Bicycle Therapeutics worth $8,148,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Cerity Partners LLC acquired a new position in shares of Bicycle Therapeutics in the 1st quarter worth approximately $113,000. Portland Investment Counsel Inc. acquired a new position in Bicycle Therapeutics in the first quarter worth $127,000. Tocqueville Asset Management L.P. grew its holdings in shares of Bicycle Therapeutics by 24.5% during the first quarter. Tocqueville Asset Management L.P. now owns 18,300 shares of the company’s stock worth $155,000 after purchasing an additional 3,600 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Bicycle Therapeutics in the first quarter valued at $214,000. Finally, Geode Capital Management LLC raised its holdings in shares of Bicycle Therapeutics by 89.0% in the second quarter. Geode Capital Management LLC now owns 40,412 shares of the company’s stock valued at $281,000 after buying an additional 19,035 shares during the last quarter. 86.15% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Tuesday. Citigroup reissued an “outperform” rating on shares of Bicycle Therapeutics in a report on Friday, October 31st. Royal Bank Of Canada restated a “sector perform” rating and issued a $11.00 price objective (down previously from $27.00) on shares of Bicycle Therapeutics in a research report on Friday, October 31st. Oppenheimer reiterated an “outperform” rating and issued a $44.00 price objective (down from $48.00) on shares of Bicycle Therapeutics in a research report on Monday, August 11th. Finally, JMP Securities set a $12.00 target price on Bicycle Therapeutics in a research note on Friday, October 31st. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.80.

Bicycle Therapeutics Stock Performance

Shares of Bicycle Therapeutics stock opened at $6.48 on Friday. The firm has a fifty day moving average of $7.56 and a two-hundred day moving average of $7.77. The stock has a market capitalization of $449.52 million, a price-to-earnings ratio of -1.79 and a beta of 1.48. Bicycle Therapeutics PLC Sponsored ADR has a 52 week low of $6.10 and a 52 week high of $22.71.

Insiders Place Their Bets

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,231 shares of the firm’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $8.41, for a total transaction of $27,172.71. Following the transaction, the chief executive officer owned 475,310 shares in the company, valued at approximately $3,997,357.10. This trade represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 8,527 shares of company stock valued at $71,738 over the last quarter. Corporate insiders own 22.90% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.